This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Extended results of the Alzheimer’s disease anti-inflammatory prevention trial


Breitner, John C., Baker, Laura D., Montine, Thomas J., Meinert, Curtis L., Lyketsos, Constantine G., Ashe, Karen H., Brandt, Jason, Craft, Suzanne, Evans, Denis E., Green, Robert C., Ismail, M. Saleem, Martin, Barbara K., Mullan, Michael J., Sabbagh, Marwan, Tariot, Pierre N.


Alzheimer's & Dementia: The Journal Of The Alzheimer's Association, Volume: 7, No.: 4, Pages.: 402-411

Year of Publication



Background: Epidemiologic evidence suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) delay onset of Alzheimer’s dementia (AD), but randomized trials show no benefit from NSAIDs in patients with symptomatic AD. The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) randomized 2,528 elderly persons to naproxen or celecoxib versus placebo for 2 years (standard deviation = 11 months) before treatments were terminated. During the treatment interval, 32 cases of AD revealed increased rates in both NSAID-assigned groups.; Methods: We continued the double-masked ADAPT protocol for 2 additional years to investigate incidence of AD (primary outcome). We then collected cerebrospinal fluid (CSF) from 117 volunteer participants to assess their ratio of CSF tau to Aβ(1-42.); Results: Including 40 new events observed during follow-up of 2,071 randomized individuals (92% of participants at treatment cessation), there were 72 AD cases. Overall, NSAID-related harm was no longer evident, but secondary analyses showed that increased risk remained notable in the first 2.5 years of observations, especially in 54 persons enrolled with cognitive impairment–no dementia (CIND). These same analyses showed later reduction in AD incidence among asymptomatic enrollees who were given naproxen. CSF biomarker assays suggested that the latter result reflected reduced Alzheimer-type neurodegeneration.; Conclusions: These data suggest a revision of the original ADAPT hypothesis that NSAIDs reduce AD risk, as follows: NSAIDs have an adverse effect in later stages of AD pathogenesis, whereas asymptomatic individuals treated with conventional NSAIDs such as naproxen experience reduced AD incidence, but only after 2 to 3 years. Thus, treatment effects differ at various stages of disease. This hypothesis is consistent with data from both trials and epidemiological studies.; Copyright © 2011 The Alzheimer’s Association. All rights reserved.

Bibtex Citation

@article{Breitner_2011, doi = {10.1016/j.jalz.2010.12.014}, url = {}, year = 2011, month = {jul}, publisher = {Elsevier {BV}}, volume = {7}, number = {4}, pages = {402--411}, author = {John C. Breitner and Laura D. Baker and Thomas J. Montine and Curtis L. Meinert and Constantine G. Lyketsos and Karen H. Ashe and Jason Brandt and Suzanne Craft and Denis E. Evans and Robert C. Green and M. Saleem Ismail and Barbara K. Martin and Michael J. Mullan and Marwan Sabbagh and Pierre N. Tariot}, title = {Extended results of the Alzheimer's disease anti-inflammatory prevention trial}, journal = {Alzheimer{textquotesingle}s {&} Dementia} }


aged, aged, 80 and over, alzheimer disease, celecoxib, cerebrospinal fluid, confidence intervals, double-blind method, female, humans, longitudinal studies, male, naproxen, neuropsychological tests, or, peptide fragments, prevention & control, proportional hazards models, psychiatric status rating scales, pyrazoles, sulfonamides, tau proteins, therapeutic use

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Cohort Study

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions, Risk Factor Modification

Risk Factor Modifications

General population health promotion

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime